Standardization of Anti-Seizure Medications Withdrawals After Seizure Remission in Young Patients With Epilepsy

NCT ID: NCT05740423

Last Updated: 2023-02-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-30

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proper period of anti-seizure medication (ASM) treamtment is important for decreasing side effect of ASM and recurrence of seizure. We evaluate reliable risk factor analysis for safe withdrawal of ASM in children with epilepsy. Futhermore, we develop the scoring system for prediction of seizure recurrence to set the standard for safe withdrawal of ASM.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proper period of anti-seizure medication (ASM) treamtment is important for decreasing side effect of ASM and recurrence of seizure. We evaluate reliable risk factor analysis for safe withdrawal of ASM in children with epilepsy. Futhermore, we develop the scoring system for prediction of seizure recurrence to set the standard for safe withdrawal of ASM.

The enroll criteria as follow:

1. patients with epilepsy or acute provoked seizure accroding to the ILAE definition
2. patients who have been 2 years of seizure free with or without ASM

The patients with seizure recurrence during follow-up or end of follow-up period of 24 months will end this stutdy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy Epilepsy in Children

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with Epilepsy or acute provoked seizure according to the ILAE guideline
* Patients with 2 years of seizure free periods

Exclusion Criteria

* Uncertain diagnosis of epilepsy or acute provoked seizure
* Patients who do not want to participate in the study
Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Health, Republic of Korea

OTHER_GOV

Sponsor Role collaborator

Korea Health Industry Development Institute

OTHER_GOV

Sponsor Role collaborator

Asan Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Min-Sun Yum

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Min-Sun Yum

Role: PRINCIPAL_INVESTIGATOR

Asan Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Asan Medical Center

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Min-Jee Kim

Role: CONTACT

821045204711

Min-Sun Yum

Role: CONTACT

+82230103386

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Min-Jee Kim

Role: primary

+821045204711

Min-Sun Yum

Role: backup

+82230103386

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HC20C0164

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

HC20C0164

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.